Mink Therapeutics, Inc. Stock Price, News & Analysis

MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the release of its first quarter 2023 financial results on May 11, 2023. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide corporate updates. The conference call will be accessible via phone and online, with dedicated dial-in numbers for participants in the USA and Canada. MiNK is advancing its pipeline of native and engineered iNKT programs aimed at treating cancer and other immune-mediated diseases, emphasizing scalable manufacturing for off-the-shelf delivery.

MiNK Therapeutics (Nasdaq: INKT) presented promising results at the AACR annual meeting for its iNKT cell therapy, agenT-797, showing effectiveness against refractory solid tumors. In a phase 1/2 trial involving heavily pretreated patients, significant tumor shrinkage of over 42% was observed in a patient with gastric cancer, maintaining response for over 9 months. The therapy, administered without toxic lymphodepletion, remained detectable for about 8 weeks, promoting immune cell infiltration into tumors. Following these results, MiNK plans to expand trials, combining agenT-797 with established therapies in additional cancer types, furthering its commitment to advancing cancer treatment options.

Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.